Abstract
Schistosomiasis is a neglected tropical disease caused by parasitic flatworms. Current treatment relies on just one partially effective drug, praziquantel (PZQ). Schistosoma mansoni Venus Kinase Receptors 1 and 2 (SmVKR1 and SmVKR2) are important for parasite growth and egg production, and are potential targets for combating schistosomiasis. VKRs consist of an extracellular Venus Flytrap Module (VFTM) linked via a transmembrane helix to a kinase domain. Here, we initiated a drug discovery effort to inhibit the activity of the SmVKR2 kinase domain (SmVKR2KD) by screening the GSK published kinase inhibitor set 2 (PKIS2). We identified several inhibitors, of which four were able to inhibit its enzymatic activity and induced phenotypic changes in ex vivo S. mansoni. Our crystal structure of the SmVKR2KDdisplays an active-like state that sheds light on the activation process of VKRs. Our data provide a basis for the further exploration of SmVKR2 as a possible drug target.
Author supplied keywords
Cite
CITATION STYLE
Mathavan, I., Liu, L. J., Robinson, S. W., El-Sakkary, N., Elatico, A. J. J., Gomez, D., … Beis, K. (2022). Identification of Inhibitors of the Schistosoma mansoni VKR2 Kinase Domain. ACS Medicinal Chemistry Letters, 13(11), 1715–1722. https://doi.org/10.1021/acsmedchemlett.2c00248
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.